FibroGen Inc
(NAS:FGEN)
$
0.4013
-0.0071 (-1.77%)
Market Cap: 39.66 Mil
Enterprise Value: 46.04 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 50/100 - Q1 2024 FibroGen Inc Earnings Call TranscriptMay 06, 2024$1.16 (+1.75%)Earnings
- Q4 2023 FibroGen Inc Earnings Call TranscriptFeb 26, 2024$1.85 (+1.65%)Earnings
- FibroGen Inc KOL Investor Event Series Part I (Virtual) TranscriptFeb 13, 2024
- Q3 2023 FibroGen Inc Earnings Call TranscriptNov 06, 2023$0.5592 (-13.62%)Earnings
- Q2 2023 FibroGen Inc Earnings Call TranscriptAug 07, 2023$1.77 (-7.33%)Earnings
- FibroGen Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- FibroGen Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 FibroGen Inc Earnings Call TranscriptMay 08, 2023$17.77 (+2.07%)Earnings
- Q4 2022 FibroGen Inc Earnings Call TranscriptFeb 27, 2023$22.51 (+1.35%)Earnings
- FibroGen Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 08, 2022
- Q3 2022 FibroGen Inc Earnings Call TranscriptNov 07, 2022$16.16 (-0.55%)Earnings
- Q2 2022 FibroGen Inc Earnings Call TranscriptAug 08, 2022$14.6 (+0.62%)Earnings
- Q1 2022 FibroGen Inc Earnings Call TranscriptMay 09, 2022$7.94 (-5.59%)Earnings
- Q4 2021 FibroGen Inc Earnings Call TranscriptFeb 28, 2022$14.07 (-3.10%)Earnings
- Q3 2021 FibroGen Inc Earnings Call TranscriptNov 09, 2021$12.08 (-0.33%)Earnings
- Q2 2021 FibroGen Inc Earnings Call TranscriptAug 09, 2021$13.79 (+0.44%)Earnings
- FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- FibroGen Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 04, 2021
- FibroGen Inc Annual Shareholders Meeting TranscriptMay 26, 2021
- FibroGen Inc at Bank of America Global Research Healthcare Conference (Virtual) - Fireside Chat TranscriptMay 13, 2021
- Q1 2021 FibroGen Inc Earnings Call TranscriptMay 10, 2021$19.42 (-4.00%)Earnings
- FibroGen Inc Provides Additional Information on Roxadustat - Conference Call TranscriptApr 06, 2021
- FibroGen Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 02, 2021
- Q4 2020 FibroGen Inc Earnings Call TranscriptMar 01, 2021$50.53 (+1.00%)Earnings
- FibroGen Inc at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- FibroGen Inc at Jefferies Virtual London Healthcare Conference TranscriptNov 19, 2020
- Q3 2020 FibroGen Inc Earnings Call TranscriptNov 05, 2020$42.46 (+1.43%)Earnings
- FibroGen Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- FibroGen Inc at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2020
- Q2 2020 FibroGen Inc Earnings Call TranscriptAug 06, 2020$41.45 (-2.81%)Earnings
- FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2020
- FibroGen Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- FibroGen Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 02, 2020
- FibroGen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Q1 2020 FibroGen Inc Earnings Call TranscriptMay 07, 2020$36.42 (+1.19%)Earnings
- Q4 2019 FibroGen Inc Earnings Call TranscriptMar 02, 2020$43.15 (+3.23%)Earnings
- FibroGen Inc at Leerink Global Healthcare Conference TranscriptFeb 25, 2020
- Q3 2019 FibroGen Inc Earnings Call TranscriptNov 11, 2019$35.4 (-14.94%)Earnings
- Q2 2019 FibroGen Inc Earnings Call TranscriptAug 08, 2019$46.5 (+2.88%)Earnings
- FibroGen Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Q1 2019 FibroGen Inc Earnings Call TranscriptMay 09, 2019$45.67 (-1.59%)Earnings
- Q4 2018 FibroGen Inc Earnings Call TranscriptFeb 27, 2019$58.66 (+2.75%)Earnings
FibroGen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020 / 03:00PM GMT
Release Date Price:
$36.28
(+0.53%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
Good day, everybody. My name is Jason Gerberry. I cover smid-cap biotech and especially pharmaceutical for Bank of America. I'm pleased to be introducing our next company presenter, FibroGen and new CEO, Enrique Conterno. FibroGen is -- most would know the company for its development of roxadustat for anemia associated with dialysis or renal disease, but the company also has an emerging early to mid-stage pipeline with pamrevlumab for fibrotic disorders.
So Enrique, first off, thanks for joining us at the conference on a virtual basis.
Enrique A. Conterno
FibroGen, Inc. - CEO & Director
No, thank you, Jason. It's a pleasure for me to be here and talk about the progress we're making at FibroGen.
Questions & Answers
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
Great. I mean, look, you're no longer new to the role, but I imagine that the opportunity with
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)